Page last updated: 2024-12-08
cohumulone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cohumulone: do not confuse with the 2,5-cyclohexadiene positional isomer by the same name; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 196915 |
| CHEBI ID | 175443 |
| SCHEMBL ID | 317724 |
| SCHEMBL ID | 13629034 |
| MeSH ID | M0409035 |
Synonyms (23)
| Synonym |
|---|
| CHEBI:175443 |
| 3,5,6-trihydroxy-4,6-bis(3-methylbut-2-enyl)-2-(2-methylpropanoyl)cyclohexa-2,4-dien-1-one |
| 142628-20-4 |
| cohumulone |
| 2,5-cyclohexadien-1-one, 3,4,5-trihydroxy-2-isobutyryl-4,6-bis(3-methyl-2-butenyl)- |
| 511-25-1 |
| unii-2y34g4nic8 |
| 5-(alpha,beta-dibromophenethyl)-5-methylhydantoin |
| 2y34g4nic8 , |
| SCHEMBL317724 |
| SCHEMBL13629034 |
| cohumulone, (-)- |
| 2,5-cyclohexadien-1-one, 3,4,5-trihydroxy-2,4-bis(3-methyl-2-buten-1-yl)-6-(2-methyl-1-oxopropyl)-, (-)- |
| (-)-3,4,5-trihydroxy-2,4-bis(3-methyl-2-buten-1-yl)-6-(2-methyl-1-oxopropyl)-2,5-cyclohexadien-1-one |
| DRSITEVYZGOOQG-UHFFFAOYSA-N |
| 3,4,5-trihydroxy-2,4-bis(3-methyl-2-butenyl)-6-(2-methyl-1-oxopropyl)-2,5-cyclohexadien-1-one, 9ci |
| Q27893896 |
| Q2981886 |
| (+/-)-cohumulone |
| 3,5,6-trihydroxy-4,6-bis(3-methylbut-2-en-1-yl)-2-(2-methylpropanoyl)cyclohexa-2,4-dien-1-one |
| DTXSID20931549 |
| DTXSID701318500 |
| gtpl12422 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| secondary alpha-hydroxy ketone | An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing one hydrogen and one organyl group. Secondary alpha-hydroxy ketones are also known as acyloins, and are formally derived from reductive coupling of two carboxylic acid groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 35.18
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.18) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||